Previous 10 | Next 10 |
home / stock / esaly / esaly news
The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gilead Sciences (NASDAQ:GILD), Galapagos (NASDAQ:GLPG) and Eisai's (OTCPK:ESALF) drug Jyseleca (filgotinib) to treat patients with moderate-to-severe active ulcerative colitis (UC), an inflammatory bowel diseas...
Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer's Disease PR Newswire The Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PD™ 2022) KOBE, Japan and ...
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting CAMBRIDGE, Mass., and TOKYO, Mar 22, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibr...
LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING PR Newswire TOKYO and CAMBRIDGE, Mass. , March 21, 2022 /PRNewswire/ -- Eis...
UBS is maintaining its buy rating on Biogen (BIIB +2.2%) despite Tuesday's announcement the biotech is taking sole commercial rights to Alzheimer's treatment Aduhelm (aducanumab) from partner Eisai (OTCPK:ESALY -0.1%). The firm has a $269 price target (~36% upside based on Tuesday's close). A...
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen TOKYO, Mar 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agre...
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments CAMBRIDGE, Mass., and TOKYO, Mar 15, 2022 - (JCN Newswire) - Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement ...
The patient advocacy groups in the U.S. have stepped up their efforts for a favorable decision on the coverage for Aduhelm and similar Alzheimer’s drugs as the developers await a final decision next month. Backed by millions of dollars in ad spending, local adverts have already co...
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting TOKYO, Mar 11, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the company will p...
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) TOKYO, Mar 9, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large ...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...